Vnitr Lek 2022, 68(1):E22-E26 | DOI: 10.36290/vnl.2022.014

Závažné zlyhávanie srdca a arytmia po protinádorovej liečbe podávanej v detstve

Xénia Faktorová1, Milan Luknár2, 3, Zuzana Zelinková1, Lucia Horniaková4, Eva Mikušková5, Michal Šašov6, Mária Szántová4, Viliam Mojto4, Beata Mladosievičová7
1 Department of Internal Medicine of the Slovak Medical University, University Hospital - St. Michael's Hospital, a.s, Bratislava
2 Department of Heart Failure and Heart Transplantation National Institute of Cardiovascular Diseases, Bratislava
3 Department of Cardiology, Faculty of Medicine, Comenius University and National Institute of Cardiovascular Diseases, Bratislava
4 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava
5 Department of Oncohematology Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava
6 Department of Arrhytmias and Cardiac Stimulation National Institute of Cardiovascular Diseases, Bratislava
7 Institute of Pathological Physiology, Department of Clinical Pathophysiology, Faculty of Medicine, Comenius University, Bratislava

Cieľom kazuistiky je popísať prípad mladého pacienta, v detstve úspešne liečeného pre non-Hodgkinov lymfóm chemoterapiou s obsahom anthracyklínu doxorubicínu s neskorším rozvojom príznakov závažného kardiovaskulárneho poškodenia 27 rokov od diagnostiky lymfómu. Pacient je dlhodobo v kompletnej remisii onkologického ochorenia. U pacienta bola započatá liečba chronického srdcového zlyhávania v súlade s najnovšími odporúčaniami vrátane implantácie kardioverter-defibrilátora, ako primárnej prevencie náhlej kardiálnej smrti. Momentálne je pacient čakateľom na transplantáciu srdca.

Keywords: antracyklíny, arytmia, srdcové zlyhávanie, implantovateľný kardioverter-defibrilátor, neskorá kardiotoxicita.

Published: February 14, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Faktorová X, Luknár M, Zelinková Z, Horniaková L, Mikušková E, Šašov M, et al.. Závažné zlyhávanie srdca a arytmia po protinádorovej liečbe podávanej v detstve. Vnitr Lek. 2022;68(1):E22-26. doi: 10.36290/vnl.2022.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bates JE, Howell RM, Liu Q et al. Therapy‑Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. J Clin Oncol 2019;37(13):1090-1101. DOI: . Go to original source... Go to PubMed...
    2. Mulrooney DA, Hyun G, Ness KK et al. Major cardiac events for adult survivors of childhood cancer diagnosed between 1970 and 1999: report from the Childhood Cancer Survivor Study cohort. BMJ 2020;368:l6794. DOI: . Go to original source... Go to PubMed...
    3. Armenian SH, Hudson MM, Mulder RL et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2015;16(3):123-136. DOI: . Go to original source... Go to PubMed...
    4. Haddy N, Diallo S, El‑Fayech C et al. Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study. Circulation 2016;133(1):31-38. DOI: . Go to original source... Go to PubMed...
    5. Children's Oncology Group. Data from October 2018. Long‑Term Follow‑Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers, Version 5. 0. Monrovia, CA: Children's Oncology Group. [2021-02-28]. Retrieved from: .
    6. Hilfiker‑Kleiner D, Ardehali H, Fischmeister R et al. Late onset heart failure after childhood chemotherapy. Eur Heart J 2019;40(10):798-800. DOI: . Go to original source... Go to PubMed...
    7. Scully RE, Lipshultz SE. Anthracycline cardiotoxicity in long‑term survivors of childhood cancer. Cardiovasc Toxicol 2007;7(2):122-128. DOI: . Go to original source... Go to PubMed...
    8. Simbre VC, Duffy SA, Dadlani GH et al. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005;7(3):187-202. DOI: . Go to original source... Go to PubMed...
    9. Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24(6):352-361. DOI: . Go to original source... Go to PubMed...
    10. Chen Y, Chow EJ, Oeffinger KC et al. Traditional cardiovascular risk factors and individual prediction of cardiovascular events in childhood cancer survivors. J Natl Cancer Inst 2020;112(3):256-265. DOI: . Go to original source... Go to PubMed...
    11. Cardinale D, et al. Early Detection of Anthracycline Cardiotoxicity and Improvement with Heart Failure Therapy. Circulation 2015;131(22):1981-1988. DOI: . Go to original source... Go to PubMed...
    12. Hines MR, Mulrooney DA, Hudson MM et al. Pregnancy‑associated cardiomyopathy in survivors of childhood cancer. J Cancer Surviv 2016;10(1):113-121. DOI: . Go to original source... Go to PubMed...
    13. Wang J, Li J, Kong F et al. Bipolar II disorder as the initial presentation of CADASIL: an underdiagnosed manifestation. Neuropsychiatr Dis Treat 2017;13:2175-2179. DOI: . Go to original source... Go to PubMed...
    14. Lesnik Oberstein SA, Jukema JW, Van Duinen SG et al. Myocardial Infarction in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Medicine 2003;82(4):251-256. DOI: . Go to original source... Go to PubMed...
    15. Urbanova D, Bubanska E, Hrebik M, Mladosievicova B. Heart transplant in a childhood leukaemia survivor: a case report. Exp Clin Transplant 2010;8(1):79-81.None< 15 Gy or noneNo screening≥ 15 < 35 GyEvery 5 years≥ 35 GyEvery 2 years< 250 mg/m2< 15 Gy or noneEvery 5 years≥ 15 GyEvery 2 years≥ 250 mg/m2undecidedEvery 2 years Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.